Travere Therapeutics: Funding, Investors & Team (Oct 2026)
Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring broad access and education for its FDA-approved therapies.
Travere Therapeutics has raised $750M across 2 funding rounds on record, the most recent an undisclosed round of $475M announced in May 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Travere Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Travere Therapeutics Funding Rounds
Travere Therapeutics raised $275M in a Post-IPO Debt announced in Mar 2022.
4.2 years later, an undisclosed round of $475M was announced in May 2026.
Travere Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Travere Therapeutics Funding Compared to Other Biotechnology Startups
Travere Therapeutics' latest round of $475M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Travere Therapeutics in Biotechnology and San Diego
Companies Similar to Travere Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Travere Therapeutics Funding FAQs
What does Travere Therapeutics do?
Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring broad access and education for its FDA-approved therapies.
How much funding has Travere Therapeutics raised?
Travere Therapeutics has raised $750M across 2 rounds on record. The most recent is an undisclosed round of $475M announced in May 2026.
When did Travere Therapeutics last raise funding?
Travere Therapeutics' most recent funding round on record is an undisclosed round of $475M, announced in May 2026.
Who is the CEO of Travere Therapeutics?
Eric Dube is listed as CEO at Travere Therapeutics.
Where is Travere Therapeutics headquartered?
Travere Therapeutics is based in San Diego, California, United States.
How many employees does Travere Therapeutics have?
Travere Therapeutics is in the 251-500 employee band.
How does Travere Therapeutics' funding compare to other Biotechnology startups?
Travere Therapeutics' latest round of $475M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Travere Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Travere Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.